Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BMTI is holding up well on a down day. This is a good sign!
MACD is nearing bullish crossover as BMTI is set for the next leg up, imo.
BMTI is oversold, new patent awarded to BMTI last week check out the BMTI iBox for more info. http://investorshub.advfn.com/boards/board.aspx?board_id=12308
A new Patent was awarded to BioMimetic Therapeutics on May 17, 2011.
Patent # (7,943,573)
"Methods for treatment of Distraction Osteogenesis using PDGF."
View the patent here:
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=7,943,573.PN.&OS=PN/7,943,573&RS=PN/7,943,573
Distraction Osteogenesis Info:
"Distraction osteogenesis, also called callus distraction, callotasis and osteodistraction is a surgical process used to reconstruct skeletal deformities and lengthen the long bones of the body. A corticotomy is used to fracture the bone into two segments, and the two bone ends of the bone are gradually moved apart during the distraction phase, allowing new bone to form in the gap. When the desired or possible length is reached, a consolidation phase follows in which the bone is allowed to keep healing. Distraction osteogenesis has the benefit of simultaneously increasing bone length and the volume of surrounding soft tissues."
Possible uses of distraction osteogenesis
Although distraction osteogenesis is most often used in the treatment of post-traumatic injuries, it is increasingly used to correct limb discrepancies caused by congenital conditions and old injuries.
A list of the possible uses of distraction osteogenesis are as follows:
Congenital deformities (birth defects):
Congenital short femur;
Fibular hemimelia (absence of the fibula, which is one of the two bones between the knee and the ankle);
Hemiatrophy (atrophy of half of the body); and
Ollier's disease.
Developmental deformities
Neurofibromatosis (a rare condition which causes overgrowth in one leg); and
Bow legs, resulting from rickets or secondary arthritis.
Post-traumatic injuries
Growth plates fractures;
Malunion or non-union (when bones do not completely join, or join in a faulty position after a fracture);
Shortening and deformity; and
Bone defects.
Infections and diseases
Osteomyelitis (a bone infection, usually caused by bacteria);
Septic arthritis (infections or bacterial arthritis); and
Poliomyelitis (a viral disease which may result in the atrophy of muscles, causing permanent deformity).
After tumors
Short stature
Achondroplasia (a form of dwarfism where arms and legs are very short, but torso is more normal in size); and
Constitutional short stature.
Cosmetic lengthening of limbs.
Source: http://en.wikipedia.org/wiki/Distraction_osteogenesis
This is good news! Another potential revenue stream in the future for BMTI
STRONG BUY!
Strong Fundamentals Driving Demand for Gold
http://forex.gftforex.com/public/item/267315
Come And Get Yo Soul Food!
BioMimetic Therapeutics Annual Report:
http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NDI4MjE4fENoaWxkSUQ9NDQ1MTAxfFR5cGU9MQ==&t=1
BioMimetic boss adds to holdings
The week after his company's latest regenerative bone product received a positive recommendation from a Food and Drug Administration panel, BioMimetic Therapeutics Chairman and CEO Sam Lynch cut a check for more than $100,000 to add to his stake in the company.
Source: http://nashvillepost.com/blogs/postbusiness/2011/5/20/biomimetic_boss_adds_to_holdings
FDA approval for Augment is expected sometime in the next 6 months. Augment received a favorable FDA Panel vote last week. BioMimetic CEO and BioMimetic VP / Regulatory & Clinical Affairs bought shares in the open market the past few days, so they must also feel Augment will get FDA approval. JPM has price target of $17 for BMTI. I think with FDA approval, $35+ is possible, imo.
Long BMTI, oversold, insiders buying. As FDA approval for Augment nears, I expect prices to trend upwards.
Another Insider Purchase!
BioMimetic VP / Regulatory & Clinical Affairs
Russell Pagano
Purchased 1,900 Shares of BMTI @ $7.9493 on 5/19
http://www.sec.gov/Archives/edgar/data/1138400/000120919111029907/xslF345X03/doc4.xml
BMTI breaking out, 1m+ option expiration today. Insider Purchases over past few days. STRONG BUY
BMTI BUY CONFIRMED!
BIOMIMETIC THERAPEUTICS INC
Our system posted a BUY CONFIRMED today. The previous SELL recommendation was issued on 04.26.2011 (23) days ago, when the stock price was 13.9700. Since then BMTI has fallen -43.09% .
BUY-IF is confirmed by a white candlestick with a higher open. The buying price is today's open ( 7.7400 ) according to the Rules of Confirmation.
Patience pays off. The market wavered a bit but finally confirmed the recent bullish formation. The dose of the previous day was not enough for a BUY-IF confirmation but today it is. The market opened with a gap up and the day’s activity resulted in a close higher than the open. This is a valid confirmation criterion. The market is now ready for a bullish move.
We hope that you bought this stock . You should watch the upward gap in the opening, wait a bit, feel the bullish tendency of the market making sure that prices stay over the opening price and then go long. Your benchmark was the opening price of the upward gap.
If you bought, continue to hold this stock until the confirmation of the next SELL-IF signal. You are on safe grounds as long as the future prices continue to trade above the benchmark price. What to do if you did not buy? Maybe, you did not have time to follow the session or you simply delegated the delicate job of confirmation to us. Well it is a bit late, but not too late. You may still find suitable prices for buying in the following sessions.
The market is currently cold for short-sellers. Avoid any short sales and cover the short positions immediately if there are any.
Source: http://americanbulls.com/StockPage.asp?CompanyTicker=BMTI&MarketTicker=NASD&TYP=S
The shorts are going to get squeezed big time! Do not let them get your shares BMTI longs!
Dead Cat Bounce, imo.
BMTI CEO buys 10,000 shares at $7.90 and 3,000 shares at $7.75 today. The President and CEO of BioMimetic Therapeutics filed a Form 4 today with the SEC. The CEO is buying BMTI stock at these levels. STRONG BUY!!!
Sec Filing: http://www.sec.gov/Archives/edgar/data/1138400/000120919111029613/xslF345X03/doc4.xml
Looking for $6.50 - $7.50 for an entry point in FRP. With no revenue guidance, I see continued selling pressure, imo.
It will be interesting to see what happens to the price of silver as the Shanghai 'commie errrr... commodity market comes online. Could go either way, imo. While I believe Silver is ultimately headed higher, the commodity correction as of late may led to lower prices in the short term before eventual commodity market reversal, imo.
BMTI had a great day and candlestick analysis indicates a trend reversal / Bullish Harami Pattern was formed today. The volume is drying up, indicating the sellers have the upper hand. The RSI and STO have bottomed I would not be suprised to see a gap up over the next few days as the shorts scramble to cover. According to http://www.shortsqueeze.com/?symbol=bmti&submit=Short+Quote%99 BMTI short interest actually INCREASED 4.07% today to 1,341,400 shares short!!! The average daily trading volume is 181,000 shares. With volume declining, BMTI has the potential to rocket back to the $12 - $13 range over the next few weeks, imo.
The past few days were great opportunities. A few months from now many will wish they had bought more @ these levels, imo.
BMTI is oversold. Glad I loaded up EOD Friday. Looking for a bounce back to ~ $13. As FDA approval for Augment nears, BMTI is an easy 5 bagger, imo.
BMTI BioMimetic Therapeutics, Inc is oversold. Looking for a nice bounce. FDA panel voted favorably for Augment. Price target is $35 + as BMTI moves closer towards FDA approval. Possible buyout / takeover candidate, imo.
BMTI is technically oversold. Last close $8.11. Looking for a bounce back to ~ $12.50 - $13.00 as Augment moves closer to FDA approval following favorable FDA panel vote, imo.
BMTI BioMimetic Therapeutics, Inc. Chart Please.
Thank$
I loaded up @ EOD courtesy of weak hands not wanting to hold over the weekend. I am very optimistic about the future of BMTI. The Augment Bone Graft and Injection products are very promising. Autograft (Traditional Bone Harvesting) is an invasive and painful procedure, and Augment is a game changer. BMTI will have a 'monopoly' with the Augment product line. Augment will undoubtedly be a cash cow for BMTI, imo.
Check this out:
BioMimetic Therapeutics Inc at Deutsche Bank Securities Inc. Health Care Conference Call from Tuesday, May 3, 2011 8:00 AM ET
http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=BMTI&item_id=3912177
I agree. Extremely oversold. Buying on the dips on BMTI today. My guess is forced covering from 3 days ago. Looking forward to next week.
Buying on the dips.
Funny how all the BMTI bashers post in CAPS.
All CAPS = 0 credibility, eom.
http://www.thelion.com/bin/aio_msg.cgi?cmd=search&msg=&si=1&tw=1&tt=1&rb=1&ih=1&fo=1&iv=1&yf=1&bg=1&sa=1&symbol=bmti
Base has been formed, inching higher as shorts get squeezed, eom.